Navigation Links
Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
Date:9/2/2010

CARY, N.C., Sept. 2 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), is launching a series of scientific seminars, "An Accelerated Path to Proof-of-Concept in Drug Development," designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase I and IIa clinical trial designs. The sessions will familiarize attendees with techniques and study designs to save time and money when bringing new drugs to market. The seven-city series starts on September 15 in Princeton, N.J., and ends on October 21 in San Diego.

"We know that pharmaceutical and biotechnology companies are under increased pressure to get drugs to market as soon as possible. Identifying viable drug candidates quickly allows resources to be used more strategically," said Dr. Troy McCall, CEO of Cetero Research. "Through this seminar series, we can share our expertise and best practices in accelerating the drug development process. Some of the techniques we will be discussing have been shown to cut clinical trial timelines in half and reduce costs by more than 10 percent."

The seminars will focus on three topics: combined Phase I and IIa studies to accelerate proof-of-concept, biomarker fit-for-purpose assays and advanced population PK/PD modeling/analysis. Industry experts will share information and real-life case studies about the accelerated proof-of-concept (AcPOC) study designs and how to select the appropriate level of validation for biomarker assays to ensure that studies meet the current guidance. In addition, Cetero executives will discuss lessons learned from conducting more than 10,000 clinical pharmacology studies in a range of therapeutic areas, working with both healthy participants and patient populations.

"Our case studies demonstrate how the AcPOC study design can combine multiple trials – including single ascending dose (SAD), multiple ascending dose (MAD), preliminary interaction and proof-of-concept (POC) – into one study," said Dr. Graham Wood, President of Clinical Operations for Cetero's Toronto and Miami facilities and one of the speakers in the series. "In one allergy study for a major pharmaceutical company, we went from first patient, first visit, to top-line POC results in just 16 weeks, instead of the average 32 weeks. The savings in time and money, as well as the ability to get actionable data earlier, are major advantages for our sponsors in today's environment."

Each seminar will last approximately two hours and feature three presentations with question and answer sessions. The series schedule is as follows:

  • September 15 — Princeton, N.J.
  • September 29 — Raleigh, N.C.
  • October 7 — Chicago
  • October 12 — Boston
  • October 13 — Philadelphia
  • October 20 — San Francisco
  • October 21 — San Diego

For more information about Cetero's seminar series or to register for a session, please visit www.cetero.com/acpocseminar, email rsvp@cetero.com or call 877-7CETERO.

About Cetero Research

Cetero Research is the leading early-stage contract research organization (CRO). With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies – more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug-development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.


'/>"/>
SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Leads Industry in Human Allergy Models
2. St. Jude Childrens Research Hospital Doctors and Scientists Team up to Fight Childhood Cancer
3. Bend Research Receives Patent for Preparing Spray-Dried Drug Dispersions Using Pressure Nozzles
4. Society of Interventional Radiology Supports Research for New M.S. Treatments
5. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
6. Embryonic Stem Cell Research in the Toilet, According to Arthritis Treatment Center
7. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
8. International Research Team Closes In On Cause of Common Form of Muscular Dystrophy
9. Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets
10. CVS Caremark Behavioral Change Research Partnership Presents Ongoing Research at Center for Disease Control Symposium
11. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... their workers from extreme heat at their worksites. Employers with workers exposed ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
Breaking Medicine News(10 mins):